Cagrilintide + Semaglutide Blend Research Compound (CS)

"Premium grade Cagrilintide + Semaglutide Blend validation."

The Cagrilintide + Semaglutide Blend (CagriSema) is a pre-measured research blend combining the long-acting amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide, for incretin and amylin pathway research. The fixed-dose combination was evaluated in the REDEFINE 1 phase 3 clinical program (Garvey et al., N Engl J Med 2025, PMID 40544433), with component pharmacology documented for semaglutide (Wilding et al., N Engl J Med 2021, PMID 33567185) and cagrilintide (Kruse et al., J Med Chem 2021, PMID 34288673). This blend research peptide is supplied lyophilized at ≥99% purity verified by HPLC, with identity confirmed by mass spectrometry and a batch-specific Certificate of Analysis (COA) included. Store lyophilized powder at −20 °C, protected from light and moisture. For laboratory research use only — not for human or animal consumption.